This study is testing a drug called ublituximab to see if it can help people with schizophrenia. You might be able to join if you are between 18 and 60 years old, have a primary diagnosis of schizophrenia, and your current treatment isn't fully working. Researchers will measure how much your symptoms improve using a scale called PANSS (Positive and Negative Syndrome Scale) after 12 weeks. The study is currently unclear about its recruitment status and plans to enroll about 60 participants.

Study design

This is a Phase 2 interventional study, meaning it's testing a specific treatment. It plans to enroll 60 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at Week 12, suggesting follow-up for at least that long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.